In Vitro Activity of Omadacycline and Comparators against Gram-Positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results

Michael D. Huband1, Michael A. Pfalter2, Jennifer M. Streit1, Helio S. Sader3, Robert K. Flamm4
1JMI Laboratories, North Liberty, Iowa
2BioMérieux, Durham, North Carolina
3Cepheid, Sunnyvale, California
4Astellas Pharma Inc., Northbrook, Illinois

INTRODUCTION

- Omadacycline is a new oxazolidinone antibiotic (previously known as AAR-540) approved by the US Food and Drug Administration (FDA) for the treatment of adults with serious bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) caused by indicated pathogens (MSSA; 98.2%S; CABP FDA breakpoint criteria), and methicillin-resistant Staphylococcus aureus (MRSA; ≤0.06 mg/L; CLSI; CABP FDA breakpoint criteria) isolates were susceptible to low concentrations of omadacycline (Table 1).

MATERIALS AND METHODS

- A total of 1,071 bacterial isolates were collected from patients in 21 medical centers located in the United States and included 688 clinical isolates from blood (12%), respiratory tract (12%), urinary tract (11%), and other sites (5% each) and 383 reference strains.

RESULTS

- Omadacycline was highly active against Staphylococcus aureus isolates (96.7% susceptible to ≤0.06 mg/L; CLSI; ABSSSI FDA breakpoint criteria) and methicillin-resistant Staphylococcus aureus (MRSA; ≤0.06 mg/L; CLSI; ABSSSI FDA breakpoint criteria) isolates were susceptible to low concentrations of omadacycline (Table 1).

CONCLUSIONS

- Omadacycline demonstrated in vitro activity against S. aureus (97.9% ≤0.06 mg/L; CLSI; ABSSSI FDA breakpoint criteria) and methicillin-resistant S. aureus (99.9% ≤0.015 mg/L; CLSI; ABSSSI FDA breakpoint criteria) isolates were inhibited by ≤0.03 mg/L of omadacycline (Table 1). 96.7% of Staphylococcus aureus (96.7%S; ABSSSI FDA breakpoint criteria) isolates were susceptible to low concentrations of omadacycline (Table 1).

ACKNOWLEDGMENTS

This study and poster presentation were funded by a research grant from Paratek Pharmaceuticals, Inc.

REFERENCES


CLSI Document M100Ed29F. Performance standards for antimicrobial susceptibility testing; Twenty-ninth informational supplement. Wayne, PA: CLSI.

Contact Information: Michael D. Huband, Associate Director, JMI Laboratories, 340 North Point Centre, Suite A, North Liberty, IA 52277, Phone: 319.355.2561, Fax: 319.355.2568, Email: michael.huband@jmi-labs.com